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Abstract
Background. Platelet transfusion is required in the acute phase of some thrombocytopenic disorders in order to prevent
potentially dangerous hemorrhages.The purpose of this study was to assess the increase in platelet count following a slow
platelet transfusion.
Methods. Patients suffering from thrombocytopenia due to various underlying diseases were enrolled in the prospective pilot
feasibility trial and were randomly divided into two groups. Standard platelet transfusion was administered in one group, while
slow transfusion was used in the other. The platelet count was examined at 1 hour, 24 hours, and 1 week following the
transfusions.
Results. Although the platelet count was higher following 1 hour after transfusion via the standard method, the count tended to
be higher 1 week after the transfusion in the slow transfusion group. This difference, however, only turned out to be statistically
signiﬁcant amongst females.
Conclusion. A therapy of slow platelet transfusion might be more effective for the prevention of platelet loss. Further studies will
be required to strengthen this hypothesis.
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Introduction
Multipleplatelettransfusionsare commonlyrequiredin
patients during the course of their treatment for a num-
ber of diseases. Alloimmunization to antigensexpressed
on platelets with refractoriness to platelet transfusion
remainsamajorprobleminthesepatients.Inadditionto
the presence of allo-antibodies directed against platelet
antigens, inadequate post-transfusion platelet counts
can be due to a number of host-related factors, such
as disseminated intravascular coagulation, splenomeg-
aly, severe infection with high fever, drug-mediated
antibodies, administration of amphotericin B, and by
administration of platelets damaged or activated during
collection or storage (1–3).
The incidence of human leukocyte antigen (HLA)
alloimmunization and platelet refractoriness inpatients
receiving repeated transfusions of cellular components
ranges between 20% and 70% (4). Although the
mechanism of accelerated platelet destruction is not
well understood, most studies have focused on non-
immune host factors as the most common cause of
refractoriness. The efﬁcacy of transfusion of non-
HLA matched platelet concentrates in these patients
has been assessed in several studies; other studies have
introduced alternatives to alleviate this problem and
improve the outcome (2,3).
Standard transfusion pumps available in hospitals
have provided an opportunity to control the transfu-
sion rate without negative impact on the platelets for
Correspondence: R. S. Moharari, MD, Imam Khomeini Street, Sina Hospital, Tehran, Iran. Fax: +98-2188276654. E-mail: moharari@sina.tums.ac.ir;
naeem.moharari@gmail.com
(Received 21 June 2010; accepted 2 March 2011)
ISSN 0300-9734 print/ISSN 2000-1967 online   2011 Informa Healthcare
DOI: 10.3109/03009734.2011.569588several years (5). Narvios et al. have introduced slow
transfusion of platelet concentrates in patients with
acute myelogenous leukemia and refractory throm-
bocytopenia as a feasible and effective alternative
method (6).
Not many other studies have been conducted to
appraise this hypothesis; moreover, available studies
have been performed in small groups of patients with
speciﬁc underlying diseases. This study compares the
increasesinplateletlevelsafterstandardandslowtrans-
fusioninpatientswithdifferentunderlyingdiseasesthat
require platelet transfusions. In this paper, we present
preliminary results of our on-going study.
Materials and methods
Design and setting
After approval of the institutional ethics board, this
prospective pilot feasibility trial was conducted on
consecutive thrombocytopenic patients referred to
the Emergency Department of Imam Khomeini Hos-
pital to receive platelets between January 2006 and
January 2007. All patients with a platelet count of
<10,000/mL and patients with platelet count between
10,000 and 50,000/mL with active bleeding attri-
buted to platelet dysfunction or thrombocytopenia
received a platelet transfusion. A platelet concentrate
was prepared from whole blood of single donors
(random donor platelets) by light centrifugation
and preparation of platelet-rich plasma followed by
re-centrifugation to prepare a single unit of concen-
trated platelets.
It should be noted that according to the setting
of our hospital all patients were ﬁr s ts c r e e n e di nt h e
emergency department. Then they were admitted
to the department in case of acute and/or emergent
problems. Some of them were later referred to a
different department. The screening physician was
informed to take a complete history of the patients
admitted with thrombocytopenia, and in case of a
platelet transfusion we were informed.
Main outcomes
Demographic data including the patients’ age,
gender, and history of their previous transfusions
were gathered. They were allocated to two groups
using a computerized random number generation
technique. In group 1, transfusion via slow platelet
transfusion was performed: 6 units of platelets were
transfused within 6 hours using transfusion pumps. In
group 2, transfusions were performed via the standard
method of transfusion: 6 units were transfused within
3 hours.
The patients’ platelet counts were measured at
four different intervals: before transfusion, 1 hour,
24 hours, and 1 week after transfusion.
Statistics
Gathered data were entered in SPSS v. 13 and ana-
lyzed. Frequencies of the continuous variables were
presented as mean and standard deviation. Student’s
t-test was used to compare the patients’ age distribu-
tion and platelet count. Therefore, repeated measures
test and the analyses of covariance (ANCOVAs) were
used to examine the impact of a factor (time of
transfusion) on a dependent variable (bone para-
meters) adjusted for differences in covariates (platelet
count). P values less than 0.05 were considered
statistically signiﬁcant.
Results
There were 56 patients, with 31 (55.4%) females
and 25 (44.6%) males in this pilot study. It should
be noted that two cases in the slow transfusion and
one case in the standard transfusion group required
re-transfusion; all three patients were excluded from
the study.
The mean age of all patients was 38.9 ± 18.8 years.
The patients were reported to have had the underlying
disease for an average of 13.2 ± 10.5 months (ranging
from 4 to 60 months); all patients had received
multiple transfusions prior to participating in our
study. There was no signiﬁcant difference between
the two groups regarding age, gender, and the
base-line platelet levels. However, the mean disease
duration was longer in the slow transfusion group
(16.4 months versus 10.0 months; P value = 0.016).
Acute myelogenous leukemia (AML) and acute
lymphocytic leukemia (ALL) were the most common
underlying diseases in our patients (Table I).
Platelet counts increased, in both groups, 1 hour
following transfusion (Table II); the increase was
greater in the standard group. In contrast to the
standard group, however, no decline was noted in
the platelet count 1 week following slow transfusion.
Repeated ANOVAs showed a signiﬁcant difference
between different time intervals for gender and trans-
fusion type.
In repeated measure tests, signiﬁcant interactions
between time and gender and between time and
transfusion type were found. Therefore, a regression
analysis evaluating platelet count at different intervals
(as the outcome) with base-line platelet, age, gender,
and the relation between gender and transfusion
type (as the predictors) was performed. The analysis
showed that the type of transfusion signiﬁcantly
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fusion, whereas gender signiﬁcantly inﬂuenced the
count after 1 week of transfusion (Figure 1). Females
responded better to transfusion compared with men
(P < 0.05).
Discussion
Several platelet transfusions in patients with contin-
uous thrombocytopenia cause the immune system to
produce antibodies against the platelet antigens.
This leads to an alloimmunization phenomenon in
which platelets become refractory to future transfu-
sions (7,8).
With the introduction of new techniques that rap-
idly and reliably identify HLA antibodies, patients at
risk for alloimmunization should be screened before
or as early as possible in their course of platelet
support. However, this method is not always sufﬁ-
ciently sensitive to detect all allo-antibodies present
(9,10). As a result, recent studies have focused on
achieving newer technologies to overcome the prob-
lem of alloimmunization. This situation, also known
as refractory thrombocytopenia, is deﬁned as abnor-
mally low platelet count increments following two or
more consecutive transfusions (11). However, the
degree of abnormality depends on several factors.
Transfusion dose (2–12  10
11), patient blood vol-
ume, and the percent of platelets sequestered in an
exchangeable splenic pool (normally about 33%)
determine the expected peripheral platelet concentra-
tion increment (12). In one study, the velocity of the
platelet transfusion appears to be a contributing factor
to refractory thrombocytopenia (6).
Slow transfusion of platelet concentrates in throm-
bocytopenic patients has been tested in various case
reports, all reported to be promising. In the study
conducted by Narvios et al., three patients weretreated
for refractory thrombocytopenia in the course of
acute myelogenous leukemia. Utilizing an alternative
method of platelet transfusion, the platelet concentrate
was infused slowly over 6 hours via a multichannel
transfusion pump. The study showed that the platelet
count increased signiﬁcantly following this method; in
addition, no side-effects were reported in these cases
(6). Similarly, this study evaluated this method in a
larger sample size and concluded that it could be
considered as an acceptable method of platelet trans-
fusion in thrombocytopenic patients.
Some earlier studies have shown both parous
women and previously transfused patients to be at
greater risk for alloimmunization to HLA, the most
common cause of alloimmune transfusion refracto-
riness (13–15). However, the ﬁndings of this study
conclude that women experienced a better response
to slow platelet transfusion than did men. Unfortu-
nately, the height and weight of the recipients were
not measured, thus making it the major limitation
of our study in this issue. Females are typically
smaller than males, and the difference in responses
to the experiment may be due to size. The difference
between men’sa n dw o m e n ’s platelet levels after slow
platelet transfusions requires further studies.















ALL 7 (53.8) 1 6 (46.2) 0
AML 5 (35.7) 1 9 (64.3) 1
Aplastic anemia 6 (50) 1 6 (50) 2
Pancytopenia 3 (60) 1 2 (40) 0
Lymphoma 6 (100) 1 0 0
Multiple myeloma 0 0 1 (100) 0
CML 0 0 4 (100) 1
Myeloproliferative dis. 1 (100) 0 0 0
Ref. = refractoriness (deﬁned as cases with low platelet count 1 hour
following transfusion).
Table II. Platelet count (10
9/L) (in the two groups) following transfusion.
Transfusion
Slow Standard P value MD CI 95%
Prior to infusion 10.5 ± 5.1 14.0 ± 8.2 0.064 -3.44 -7.09 0.20
1 hour following infusion 30.9 ± 16.8 47.5 ± 29.0 0.011 -16.65 -29.30 -4.00
24 hours following infusion 35.0 ± 26.4 41.2 ± 29.6 0.423 -6.20 -21.63 9.22
1 week after infusion 48.5 ± 68.8 33.8 ± 21.9 0.355 14.76 -17.56 47.09
MD = mean difference; CI 95% = conﬁdence interval 95%.
214 A. Habibi et al.Conclusion
The present study showed that patients who received
slow platelet transfusion were less prone to platelet
decline after 1 week, even though the platelet count
was higher 1 hour following transfusion via a standard
method.
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Figure 1. Platelet count (10
9/L) following standard (broken lines) or slow (full lines) transfusion in males (A) and females (B).
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